Skip to main content

News

Upadacitinib Clinical Efficacy in Psoriatic Arthritis

McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.

HLA B27 Iritis - RNL 2021 Highlights

The Spondyloarthritis Advances pod presented during the RheumNow Live 2021 conference featured three speakers, including an excellent lecture by Dr. Robert Wang, ophthalmology, on HLA B27 iritis and practical tips for rheumatologists. 

Aortic Calcification and Lumbar Fracture Risk in Older Men

Fractures of the spine and abdominal aortic calcification (AAC) can both be visualized with spinal imaging; a new report shows that finding both radiographic vertebral fracture and AAC on the same lateral spine images may predict the risk of future incident major osteoporotic fracture in older me

Hypertension Unaffected by Urate Lowering Therapy

Does uric acid contribute to the risk of hypertension (HTN)?  A recent cohort trial shows that allopurinol in young adults does not sufficiently lower blood pressure (BP).

Psoriatic Disease Management - RNL 2021 Highlights

This year’s coverage of psoriatic arthritis was once again, both exciting and informative. Topics included an overview of the latest therapeutic options, an excellent discussion on psoriasis specifically, and the epidemiology of psoriatic arthritis. 

Serious Infections Still Common in Vasculitis

MedPage Today

Serious infections occurred more frequently among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis who were given induction therapy with cyclophosphamide compared with rituximab (Rituxan), Greek researchers found.

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.

FDA Panel Rejects Tanezumab for Osteoarthritis

A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).

Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights

In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning. In the Day 1 learning pods, the audience was given a tour of the new drugs in development for RA.

Safety of Paternal DMARD or Biologic Use

A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.

RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout

Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.

×